Novartis India (BOM:500672) Piotroski F-Score: 5 (As of Jul. 05, 2026) — 17% Below Median


BOM:500672 Novartis India Ltd BOM:500672
59 GF Score
Price ₹1,469.15
GF Value ₹927.96
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Novartis India Piotroski F-Score?

Novartis India BOM:500672 +1.13% 59 Piotroski F-Score is 5 as of Jul. 05, 2026, which is 17% below its 10-year median of 6.00. GuruFocus rates BOM:500672 with a GF Score™ of 59/100 and a GF Value™ of ₹927.96 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 979 Drug Manufacturers companies, Novartis India ranks better than 61.39% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Novartis India has an F-score of 5 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Novartis India's Piotroski F-Score or its related term are showing as below:

BOM:500672' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 6   Max: 8
Current: 5

During the past 13 years, the highest Piotroski F-Score of Novartis India was 8. The lowest was 3. And the median was 6.

Novartis India  (BOM:500672) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Novartis India Piotroski F-Score Related Terms


Novartis India Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Novartis India's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novartis India Piotroski F-Score Chart

Novartis India Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.00 6.00 6.00 8.00 5.00

Novartis India Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.00 0.00 0.00 0.00 5.00

BOM:500672 vs ZTS, UTHR: Piotroski F-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Novartis India's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novartis India Piotroski F-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Novartis India's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Novartis India's Piotroski F-Score falls into.


BOM:500672
59GF Score
Novartis India Ltd BOM:500672
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was ₹932 Mil.
Cash Flow from Operations was ₹467 Mil.
Revenue was ₹3,543 Mil.
Gross Profit was ₹1,560 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was (9478.1 + 9782.7) / 2 = ₹9630.4 Mil.
Total Assets at the begining of this year (Mar25) was ₹9,478 Mil.
Long-Term Debt & Capital Lease Obligation was ₹16 Mil.
Total Current Assets was ₹7,683 Mil.
Total Current Liabilities was ₹1,450 Mil.
Net Income was ₹1,009 Mil.

Revenue was ₹3,563 Mil.
Gross Profit was ₹1,535 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was (9249.3 + 9478.1) / 2 = ₹9363.7 Mil.
Total Assets at the begining of last year (Mar24) was ₹9,249 Mil.
Long-Term Debt & Capital Lease Obligation was ₹32 Mil.
Total Current Assets was ₹7,458 Mil.
Total Current Liabilities was ₹1,421 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Novartis India's current Net Income (TTM) was 932. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Novartis India's current Cash Flow from Operations (TTM) was 467. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=931.8/9478.1
=0.09831084

ROA (Last Year)=Net Income/Total Assets (Mar24)
=1009/9249.3
=0.10908934

Novartis India's return on assets of this year was 0.09831084. Novartis India's return on assets of last year was 0.10908934. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Novartis India's current Net Income (TTM) was 932. Novartis India's current Cash Flow from Operations (TTM) was 467. ==> 467 <= 932 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=15.7/9630.4
=0.00163025

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=32.1/9363.7
=0.00342813

Novartis India's gearing of this year was 0.00163025. Novartis India's gearing of last year was 0.00342813. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=7682.5/1449.7
=5.29937228

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=7458.2/1420.5
=5.25040479

Novartis India's current ratio of this year was 5.29937228. Novartis India's current ratio of last year was 5.25040479. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Novartis India's number of shares in issue this year was 24.69. Novartis India's number of shares in issue last year was 24.688. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=1559.6/3543.3
=0.44015466

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=1534.5/3562.7
=0.43071266

Novartis India's gross margin of this year was 0.44015466. Novartis India's gross margin of last year was 0.43071266. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=3543.3/9478.1
=0.37384075

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=3562.7/9249.3
=0.38518591

Novartis India's asset turnover of this year was 0.37384075. Novartis India's asset turnover of last year was 0.38518591. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+0+0+1+1+0+1+0
=5

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Novartis India has an F-score of 5 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 5 mean?
Novartis India (BOM:500672) has a Piotroski F-Score of 5 as of Jul. 05, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Novartis India and its competitors. This is 17% below median its historical median of 6.00. Over the past decade, Novartis India's Piotroski F-Score has ranged from 3.00 to 8.00. According to the industry distribution chart, Novartis India ranks #378 out of 979 companies in the Drug Manufacturers industry, placing it in the top 38.6%.
Is Novartis India's Piotroski F-Score too high?
Novartis India's current Piotroski F-Score of 5 is 17% below median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 8.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. Novartis India's value of 5 is 0% at this industry median. Based on the distribution chart, Novartis India ranks #378 out of 979 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Novartis India has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Novartis India's Piotroski F-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Novartis India ranks #378 out of 979 companies for Piotroski F-Score. This puts Novartis India in the upper half of its industry. The industry median Piotroski F-Score is 5.00. Novartis India's value of 5 is 0% at this benchmark. Historically, Novartis India's own Piotroski F-Score has ranged from 3.00 to 8.00 over the past decade. While the company's 10-year median is 6.00 vs. the industry median of 5.00, Novartis India has consistently been at the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 979 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Novartis India's current Piotroski F-Score of 5 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Novartis India and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Novartis India's current Piotroski F-Score is 5, which is 17% below median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novartis India stock overvalued right now?
Based on GuruFocus' analysis, Novartis India (BOM:500672) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹927.96, compared to a current price of ₹1,469.15 — trading 58.3% above its estimated fair value. The current Piotroski F-Score is 5, which is 17% below median its 10-year median of 6.00 and 0% at the Drug Manufacturers industry median of 5.00. Novartis India's overall GF Score™ is 59/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Novartis India (BOM:500672), the current Piotroski F-Score is 5 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Novartis India (BOM:500672) Overvalued in 2026?

Based on GuruFocus' analysis, Novartis India stock appears to be overvalued. The current stock price of ₹1,469.15 is trading 58.3% above its estimated GF Value™ of ₹927.96. GuruFocus considers Novartis India to be Significantly Overvalued.

Key valuation signals for BOM:500672:

  • Piotroski F-Score: 5 (17% below median its 10-year median of 6.00)
  • GF Value™: ₹927.96 vs. price of ₹1,469.15 (58.3% above fair value)
  • GF Score™: 59/100 with 7 warning signs
  • Industry Position: 0% at the Drug Manufacturers median (#378 of 979)

No single metric tells the full story. See the BOM:500672 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Novartis India Business Description

Other Exchanges NOVARTIND:India
Address Inspire BKC, Part of 601 & 701, Bandra Kurla Complex, Bandra (East), Mumbai, MH, IND, 400 051
Novartis India Ltd is an Indian-based pharmaceutical company. The company is engaged in the trading of Drugs and Pharmaceuticals. It derives revenue from operations in India. The company operates in a single business segment, namely Pharmaceutical Business. Its Pharmaceutical business focuses on Bone and Pain, Transplantation Immunology, and Neurosciences.
59GF Score

Get the complete analysis for BOM:500672

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,469.15
Price
₹927.96
GF Value